Treatment With Cilostazol Improves Endothelial Function in Patients With Ischemic Stroke Taking Clopidogrel
Stroke(2019)
摘要
Background: Impairment of endothelial function is associated with atherosclerosis. Cilostazol is an antiplatelet drug that inhibits phosphodiesterase III, and has the potential to improve endothelial function. The prospective, open-label, randomized trial to evaluate the safety and efficacy of dual antiplatelet therapy involving cilostazol for secondary ischemic stroke prevention is ongoing (The Cilostazol Stroke Prevention Study for Antiplatelet Combination; CSPS.com) (Int J Stroke Vol 10, Feb 2015, 253). Objective: The purpose of this study was to clarify the effect of cilostazol in addition to clopidogrel on endothelial function in patients with ischemic stroke. Material and Methods: This study was a sub-study of CSPS.com, and registered in clinical trial (UMIN 000026672). The subjects were enrolled in our hospital from ischemic stroke patients taking clopidogrel after 8-180 days. They were randomly assigned into two groups, one with adding cilostazol on clopidogrel (CIL group), and other without cilos...
更多查看译文
关键词
cilostazol,clopidogrel,ischemic stroke,abstract wp539,endothelial function
AI 理解论文
溯源树
样例
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要